Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China
Article in Intelligent Pharmacy (September 2023)
The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.
Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change
Article in Systematic Reviews (December 2022)
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
Article in World Journal of Urology (December 2022)